214 related articles for article (PubMed ID: 12889738)
21. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.
Mankoff DA; Dehdashti F; Shields AF
Neoplasia; 2000; 2(1-2):71-88. PubMed ID: 10933070
[TBL] [Abstract][Full Text] [Related]
22. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography in cancer research and treatment.
Mandelkern M; Raines J
Technol Cancer Res Treat; 2002 Dec; 1(6):423-39. PubMed ID: 12625770
[TBL] [Abstract][Full Text] [Related]
24. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography in oncology.
Leskinen-Kallio S
Clin Physiol; 1994 May; 14(3):329-35. PubMed ID: 8026150
[TBL] [Abstract][Full Text] [Related]
26. PET for in vivo pharmacokinetic and pharmacodynamic measurements.
Gupta N; Price PM; Aboagye EO
Eur J Cancer; 2002 Nov; 38(16):2094-107. PubMed ID: 12387835
[TBL] [Abstract][Full Text] [Related]
27. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas.
Hara T; Kondo T; Hara T; Kosaka N
J Neurosurg; 2003 Sep; 99(3):474-9. PubMed ID: 12959432
[TBL] [Abstract][Full Text] [Related]
28. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements.
Cohade C; Wahl RL
Semin Nucl Med; 2003 Jul; 33(3):228-37. PubMed ID: 12931324
[TBL] [Abstract][Full Text] [Related]
29. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
30. The role of positron emission tomography in pharmacokinetic analysis.
Fischman AJ; Alpert NM; Babich JW; Rubin RH
Drug Metab Rev; 1997 Nov; 29(4):923-56. PubMed ID: 9421680
[TBL] [Abstract][Full Text] [Related]
31. Fundamentals of positron emission tomography and applications in preclinical drug development.
Cherry SR
J Clin Pharmacol; 2001 May; 41(5):482-91. PubMed ID: 11361044
[TBL] [Abstract][Full Text] [Related]
32. Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
Price P
Br J Cancer; 2000 Aug; 83(3):281-3. PubMed ID: 10917538
[No Abstract] [Full Text] [Related]
33. Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography.
Hutchinson OC; Collingridge DR; Barthel H; Price PM; Aboagye EO
Curr Pharm Des; 2003; 9(11):931-44. PubMed ID: 12678876
[TBL] [Abstract][Full Text] [Related]
34. Kinetic analysis of 18F-FLT PET in lung tumors.
Bading JR
J Nucl Med; 2012 Mar; 53(3):506; author reply 506-507. PubMed ID: 22294484
[No Abstract] [Full Text] [Related]
35. Non-invasive radiotracer imaging as a tool for drug development.
Gibson RE; Burns HD; Hamill TG; Eng WS; Francis BE; Ryan C
Curr Pharm Des; 2000 Jul; 6(10):973-89. PubMed ID: 10828297
[TBL] [Abstract][Full Text] [Related]
36. Radiopharmaceuticals for brain imaging.
Saha GB; MacIntyre WJ; Go RT
Semin Nucl Med; 1994 Oct; 24(4):324-49. PubMed ID: 7817203
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.
Hooft L; Hoekstra OS; Devillé W; Lips P; Teule GJ; Boers M; van Tulder MW
J Clin Endocrinol Metab; 2001 Aug; 86(8):3779-86. PubMed ID: 11502811
[TBL] [Abstract][Full Text] [Related]
38. [Neurotransmission in human brains measured by positron emission tomography (PET)].
Yanai K
Nihon Yakurigaku Zasshi; 1997 Jun; 109(6):259-70. PubMed ID: 9253773
[TBL] [Abstract][Full Text] [Related]
39. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
[TBL] [Abstract][Full Text] [Related]
40. Measurement of local cerebral blood flow and metabolism in man with positron emission tomography.
Raichle ME
Fed Proc; 1981 Jun; 40(8):2331-4. PubMed ID: 6972328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
